Focus Partners Advisor Solutions LLC Cuts Position in Abbott Laboratories $ABT

Focus Partners Advisor Solutions LLC trimmed its position in shares of Abbott Laboratories (NYSE:ABT) by 85.6% during the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 3,128 shares of the healthcare product maker’s stock after selling 18,604 shares during the period. Focus Partners Advisor Solutions LLC’s holdings in Abbott Laboratories were worth $419,000 as of its most recent SEC filing.

Other hedge funds have also recently bought and sold shares of the company. Carr Financial Group Corp lifted its position in shares of Abbott Laboratories by 2.0% during the third quarter. Carr Financial Group Corp now owns 3,880 shares of the healthcare product maker’s stock worth $520,000 after purchasing an additional 76 shares in the last quarter. Tortoise Investment Management LLC lifted its holdings in Abbott Laboratories by 10.7% during the 2nd quarter. Tortoise Investment Management LLC now owns 795 shares of the healthcare product maker’s stock worth $108,000 after buying an additional 77 shares in the last quarter. Gemmer Asset Management LLC grew its stake in shares of Abbott Laboratories by 2.9% in the third quarter. Gemmer Asset Management LLC now owns 2,750 shares of the healthcare product maker’s stock worth $368,000 after acquiring an additional 78 shares in the last quarter. Global Financial Private Client LLC increased its position in shares of Abbott Laboratories by 3.3% during the third quarter. Global Financial Private Client LLC now owns 2,469 shares of the healthcare product maker’s stock worth $331,000 after acquiring an additional 79 shares during the period. Finally, Citizens & Northern Corp boosted its holdings in Abbott Laboratories by 0.4% in the third quarter. Citizens & Northern Corp now owns 21,875 shares of the healthcare product maker’s stock valued at $2,930,000 after purchasing an additional 79 shares during the period. Institutional investors and hedge funds own 75.18% of the company’s stock.

Abbott Laboratories Price Performance

ABT stock opened at $112.69 on Tuesday. The business has a 50 day moving average price of $115.86 and a 200 day moving average price of $124.44. The company has a quick ratio of 1.18, a current ratio of 1.58 and a debt-to-equity ratio of 0.19. The stock has a market cap of $195.82 billion, a price-to-earnings ratio of 30.29, a PEG ratio of 1.74 and a beta of 0.74. Abbott Laboratories has a fifty-two week low of $105.27 and a fifty-two week high of $139.15.

Abbott Laboratories (NYSE:ABT) last announced its quarterly earnings results on Thursday, January 22nd. The healthcare product maker reported $1.50 EPS for the quarter, meeting the consensus estimate of $1.50. The company had revenue of $11.46 billion for the quarter, compared to analyst estimates of $11.80 billion. Abbott Laboratories had a net margin of 14.72% and a return on equity of 17.73%. The firm’s revenue was up 4.4% on a year-over-year basis. During the same period in the prior year, the firm posted $1.34 earnings per share. Abbott Laboratories has set its Q1 2026 guidance at 1.120-1.180 EPS and its FY 2026 guidance at 5.550-5.800 EPS. Equities research analysts anticipate that Abbott Laboratories will post 5.14 earnings per share for the current fiscal year.

Abbott Laboratories Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, May 15th. Investors of record on Wednesday, April 15th will be given a $0.63 dividend. The ex-dividend date of this dividend is Wednesday, April 15th. This represents a $2.52 dividend on an annualized basis and a yield of 2.2%. Abbott Laboratories’s payout ratio is 67.74%.

Wall Street Analyst Weigh In

Several equities research analysts have weighed in on the company. Sanford C. Bernstein cut their price target on Abbott Laboratories from $154.00 to $125.00 and set an “outperform” rating on the stock in a report on Friday, January 23rd. Royal Bank Of Canada cut their target price on shares of Abbott Laboratories from $147.00 to $135.00 and set an “outperform” rating on the stock in a research note on Friday, January 23rd. BTIG Research decreased their price target on shares of Abbott Laboratories from $145.00 to $140.00 and set a “buy” rating for the company in a research note on Tuesday, February 17th. The Goldman Sachs Group lowered their price target on shares of Abbott Laboratories from $152.00 to $140.00 and set a “buy” rating for the company in a report on Friday, January 23rd. Finally, Citigroup reduced their price objective on shares of Abbott Laboratories from $155.00 to $140.00 and set a “buy” rating on the stock in a report on Friday, January 23rd. Two investment analysts have rated the stock with a Strong Buy rating, fifteen have given a Buy rating and four have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, Abbott Laboratories has an average rating of “Moderate Buy” and a consensus price target of $136.37.

Insider Transactions at Abbott Laboratories

In other news, EVP Elizabeth C. Cushman sold 263 shares of the business’s stock in a transaction dated Monday, March 2nd. The stock was sold at an average price of $115.58, for a total value of $30,397.54. Following the completion of the sale, the executive vice president directly owned 38,573 shares of the company’s stock, valued at approximately $4,458,267.34. The trade was a 0.68% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, VP John A. Jr. Mccoy sold 585 shares of the firm’s stock in a transaction that occurred on Monday, March 2nd. The stock was sold at an average price of $115.58, for a total value of $67,614.30. Following the transaction, the vice president owned 24,628 shares in the company, valued at $2,846,504.24. This represents a 2.32% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 3,055 shares of company stock valued at $353,097 over the last quarter. 0.46% of the stock is owned by corporate insiders.

Abbott Laboratories Company Profile

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.